# Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment

> **NCT03531827** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 4 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer
- Prostate Neoplasms

## Interventions

- **DRUG:** enzalutamide
- **DRUG:** CRLX101

## Key facts

- **NCT ID:** NCT03531827
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-26
- **Primary completion:** 2021-05-15
- **Final completion:** 2021-06-01
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study was closed for toxicity.
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03531827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03531827, "Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03531827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*